Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Multiple myeloma / Plasma cell neoplasm
Results 1-25 of 250 for your search:
Start Over
Lenalidomide or Observation in Treating Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E3A06, NCI-2011-02057, CDR0000682012, ECOG-E3A06, NCT01169337
Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 10-106, NCI-2010-02211, IFM/DFCI 2009, NCT01208662
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 20090482, NCI-2013-00401, NCT01345019
Melphalan with or without Busulfan before Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: 2010-0071, NCI-2011-02760, cs2010-0032635MA, NCT01413178
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AB06002, NCI-2013-00616, NCT01470131
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-4047-MM-007, NCI-2013-00024, NCT01734928
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: C16014, NCI-2013-01188, 163325, 2013-000326-54, U1111-1158-2646, NCT01850524
Bortezomib or Carfilzomib with Lenalidomide and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: E1A11, NCI-2012-02608, ECOG-E1A11, NCT01863550
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C16019, NCI-2015-00343, 1036024001, 173116, 2013-002076-41, C16019CTIL, NL.47795.029.14, U1111-1155-8695, NCT02181413
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR104762, NCI-2015-01114, 2014-002273-11, 54767414MMY3008, NCT02252172
A Study of Oral Ixazomib Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: C16021, NCI-2016-00109, 1046003327, 153300410A0048, 2014-001394-13, JapicCTI-152873, REec-2015-1414, U1111-1160-1702, NCT02312258
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
Phase: Phase III
Type: Natural history/Epidemiology
Age: 18 to 70
Trial IDs: BMTCTN07LT, NCI-2015-01752, U01HL069294-05, NCT02322320
A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CFZ014, NCI-2015-01208, 2014-005325-12, NCT02412878
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C16011, NCI-2012-02752, 2011-005468-10, C16011-CTIL, NL41603.028.12, U1111-1164-7621, NCT01659658
The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: NEOD001-CL002, NCI-2015-00566, NCT02312206
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A061402, NCI-2015-00323, NCT02516423
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Vaccine Therapy with or without Cyclophosphamide in Treating Patients with Recurrent or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC038C, NCI-2009-01194, Mod06-005263-65, MAYO-MC038C, MAYO-06-005263, NCT00450814
Plerixafor and Bortezomib in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 08-273, NCI-2009-01123, NCT00903968
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TED10893, NCI-2010-02332, U1111-1116-5472, NCT01084252
Start Over